OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Files An 8-K Other EventsItem 8.01
OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Files An 8-K Other Events
Other Events.
Obalon Therapeutics, Inc. (the “Company”) will hold its annual meeting of stockholders (the “2017 Annual Meeting”) on June 6, 2017 at 8 a.m. Pacific time, at the Company’s principal executive offices, 5421 Avenida Encinas, Suite F, Carlsbad, California 92008. Holders of record at the close of business on April 19, 2017 will be entitled to vote at the meeting.
Any stockholder seeking to bring business before the 2017 Annual Meeting or to nominate a director at the 2017 Annual Meeting must provide timely notice thereof in writing, as set forth in the Company’s Amended and Restated Bylaws (the “Bylaws”). Specifically, the stockholder’s notice must be delivered to the Secretary of the Company at the principal executive offices of the Company no later than the close of business on April 14, 2017 (which is the tenth day following the first public announcement of the date of the 2017 Annual Meeting). Any notice of proposed business or nomination must comply with the specific requirements set forth in the Bylaws.
About OBALON THERAPEUTICS, INC. (NASDAQ:OBLN)
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial. OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Recent Trading Information
OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) closed its last trading session up +0.28 at 10.82 with 23,027 shares trading hands.
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial. OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Recent Trading Information
OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) closed its last trading session up +0.28 at 10.82 with 23,027 shares trading hands.
